GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 06, 2025 |
Mar. 07, 2025 |
Mar. 04, 2025 |
Nov. 13, 2024 |
Oct. 14, 2024 |
Oct. 07, 2024 |
Jul. 11, 2024 |
Mar. 14, 2024 |
Mar. 08, 2024 |
Jan. 21, 2025 |
Dec. 31, 2024 |
Nov. 29, 2024 |
Aug. 23, 2024 |
Mar. 25, 2024 |
Mar. 31, 2025 |
Mar. 31, 2024 |
|
| Working capital deficit | $ (12,878,438) | |||||||||||||||
| Cash | $ 24,142 | |||||||||||||||
| Common stock price per share | $ 0.31 | $ 0.75 | $ 0.001 | $ 0.001 | ||||||||||||
| Lump sum payment of amortization | $ 275,000 | |||||||||||||||
| Net cash used in operating activities | $ (689,623) | $ (339,668) | ||||||||||||||
| Gross Proceeds | 633,100 | 175,880 | ||||||||||||||
| Conversion price | $ 0.40 | |||||||||||||||
| Exercise price of warrants maximum | 1.50 | |||||||||||||||
| Exercise price of warrants minimum | $ 1.00 | |||||||||||||||
| Debt conversion, description | $0.60 per share. In exchange for the modification, the Company issued 75,000 shares of restricted stock to the debt holder at $0.33 per share for a total value of $24,750 | |||||||||||||||
| Common stock shares issued | 500,000 | |||||||||||||||
| Retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra | |||||||||||||||
| Common stock purchase | 500,000 | |||||||||||||||
| Exercise price | $ 1.00 | |||||||||||||||
| Proceeds from notes payable | $ 0 | $ 200,000 | ||||||||||||||
| Mr Lucido [Member] | ||||||||||||||||
| Common stock price per share | $ 0.41 | $ 0.34 | ||||||||||||||
| Promissory note outstanding | $ 725,000 | $ 200,000 | ||||||||||||||
| Common stock shares issued | 1,770,452 | 585,394 | ||||||||||||||
| Related party advances | $ 100,000 | |||||||||||||||
| Thomas Welch [Member] | ||||||||||||||||
| Common stock price per share | $ 0.39 | $ 0.31 | ||||||||||||||
| Common stock shares issued | 103,627 | 500,000 | ||||||||||||||
| Professional fees | $ 40,000 | |||||||||||||||
| Upfront purchase price | $ 400,000 | |||||||||||||||
| Retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra. The Company shall also pay to the Seller a royalty equal to 3% of the Net Sales of Lucemyra and 3% of the Net Distributable Profits of the generic version of Lucemyra on a calendar quarter basis. Royalty payments shall commence on the date of the acquisition and shall continue for a period of 5 years following the date of the acquisition. | |||||||||||||||
| Common stock purchase | 500,000 | |||||||||||||||
| Exercise price | $ 1.00 | |||||||||||||||
| Investors [Member] | ||||||||||||||||
| Common stock shares issued | 15,000 | 15,000 | ||||||||||||||
| Gross Proceeds | $ 15,000 | $ 13,350 | ||||||||||||||
| Exercise price | $ 1.00 | $ 0.89 | ||||||||||||||
| Unsecured Promissory Note Related Third Party [Member] | ||||||||||||||||
| Conversion price | $ 0.75 | 0.75 | $ 0.75 | $ 0.75 | $ 0.75 | |||||||||||
| Convertible conversion price decrease | 1.50 | 1.50 | 1.00 | 1.50 | 1.00 | |||||||||||
| Convertible conversion price increase | 2.00 | 2.00 | 1.50 | 2.00 | $ 2.00 | |||||||||||
| Debt instrument term | 9 months | |||||||||||||||
| Exercise price | $ 1.00 | $ 1.00 | $ 0.60 | $ 1.00 | $ 0.60 | |||||||||||
| Proceeds from notes payable | $ 200,000 | |||||||||||||||
| Restricted stock shares issued | 79,500 | 12,500 | 37,500 | 1.00 | 50,000 | 25,000 | 75,000 | 50,000 | 75,000 | |||||||
| Interest rate | 8.00% | |||||||||||||||
| Restricted stock price per share | $ 0.35 | $ 0.31 | $ 0.30 | $ 26,000 | $ 0.52 | $ 0.38 | $ 0.30 | $ 0.30 | $ 0.33 | |||||||
| Restricted stock value | $ 27,825 | $ 3,857 | $ 11,250 | $ 26,000 | $ 26,000 | $ 9,500 | $ 22,500 | $ 15,000 | $ 24,750 | |||||||
| Debt instrument lum sum payment | $ 61,250 | $ 177,000 | $ 275,000 | $ 275,000 | ||||||||||||
| Debt instrument maturity start date | Jan. 25, 2024 | Sep. 06, 2024 | Aug. 10, 2024 | Sep. 08, 2024 | ||||||||||||
| Debt instrument maturity end date | Jan. 31, 2025 | Feb. 06, 2025 | Sep. 30, 2024 | Oct. 31, 2024 | ||||||||||||
| Amendment description | On February 28, 2025, the Company entered into a fourth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2025 to February 28, 2026 | On February 28, 2025, the Company entered into a fifth amendment agreement to such promissory note. In accordance with the amendment, the parties agreed to modify the maturity date of the note from February 28, 2025 to February 28, 2026 | ||||||||||||||
| February 22, 2024 [Member] | ||||||||||||||||
| Description of funding | The grant provides for (i) $4,131,123 in funding during the first year, (ii) $3,638,268 during the second-year, and (iii) $3,260,586 during the third-year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds | |||||||||||||||
| Award granted by third party | $ 11,029,977 | |||||||||||||||